Johnson & Johnson News Daily

# Johnson & Johnson Stock Analysis: Trading at $235.64 with Bullish Analyst Outlook | March 2026 Market Update

Discover the latest Johnson & Johnson (J&J) stock performance and analyst ratings in this comprehensive market update. Currently trading at $235.64 with strong institutional support, J&J shares are drawing significant attention from major Wall Street firms including HSBC, Goldman Sachs, and Morgan Stanley—all issuing buy ratings with price targets up to $280.

In this episode, we analyze:
- **Current stock performance**: 49.6% year-to-date gains and 29.33% six-month growth
- **Analyst price targets**: Ranging from $262 to $280, suggesting continued upside potential
- **Market capitalization**: $727.24 bi...

# Johnson & Johnson Stock Analysis: FDA Approval Drives Bullish Momentum Despite Trading Dip | JNJ Stock Update March 2024

Johnson & Johnson (NYSE: JNJ) stock closed at $237.28 on March 18th, experiencing a modest 0.4% decline amid lower-than-average trading volume. This podcast episode provides comprehensive coverage of JNJ's recent market performance, including groundbreaking FDA approval news and multiple analyst upgrades.

**Key highlights include:**

- **Major FDA Approval:** J&J's oral psoriasis pill receives FDA clearance, with Guggenheim projecting over $8 billion in peak annual sales
- **Analyst Upgrades:** Goldman Sachs reiterates buy rating with $265 price target; HSBC raises target to $280...

# Johnson & Johnson Stock Analysis: Trading at $237 with Strong Market Cap and FDA Approval Boost | JNJ Stock Update 2026

Dive into our comprehensive Johnson & Johnson (JNJ) stock analysis as shares trade at $237 with a robust $571 billion market cap. In this episode, we explore JNJ's current market position, including below-average trading volumes of 6.81 million shares and its position 6% below the 52-week high of $251.71.

**Key highlights covered:**
- Current P/E ratio of 20.61 and attractive 2.2% dividend yield for income investors
- Bank of America Securities raises price target to $253 on updated revenue projections
- Morgan Stanley's Overweight...

# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Market Performance & Analyst Outlook | Investment Podcast

**Podcast Episode Description:**

Dive deep into Johnson & Johnson (JNJ) stock performance in this comprehensive market analysis episode. We examine JNJ's recent trading activity showing the stock at $243.22 on March 16, 2026, with a massive $573.82 billion market cap, ranking it as the 19th most valuable company globally.

Discover key investment insights including:
- Recent price movements and trading volume analysis
- Bullish analyst ratings from HSBC ($280 price target) and Citigroup ($274 target)
- 52-week trading range from $146.36 to $248.56
- Year-over-year market cap...

# Johnson & Johnson (JNJ) Stock Analysis: Trading Near 52-Week High with Positive Analyst Outlook | March 2026 Update

Dive into the latest **Johnson & Johnson stock (JNJ) analysis** for March 2026. In this episode, we cover JNJ's trading performance, closing at $243.22 on March 16, 2026, near its 52-week high of $251.71 with a massive $582 billion market cap.

**Key topics include:**
- Recent **insider trading activity** including Executive VP Vanessa Broadhurst's share sale
- **Institutional ownership** at 69.55% with Norges Bank's $4.88 billion position
- Breakthrough **Erda-iDRS clinical trial results** for bladder cancer treatment
- **Analyst upgrades** from Bank of America ($253), HSBC ($265), and...

# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Price Forecast & Analyst Outlook | Stock Market Podcast

Discover the latest Johnson & Johnson (JNJ) stock analysis for March 2026 in this comprehensive podcast episode. Trading at $241.52 as of March 16, 2026, JNJ stock demonstrates defensive strength amid market volatility.

**Key highlights covered:**
- Current JNJ stock price and trading range ($241-$245)
- Short-term price forecasts: potential rise to $249.32 by Q1 end
- Analyst upgrades: Daiwa Securities raises price target to $237 with outperform rating
- Long-term projections reaching $270 by late March 2026
- Revenue target: $100 billion for fiscal year 2026
...

# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Trading Update & Price Forecast | Podcast Episode Description

Dive into the latest **Johnson & Johnson stock (JNJ) analysis** as of March 13, 2026, with comprehensive market insights and price predictions. Trading at $242.04, JNJ demonstrates **strong year-to-date performance** with gains of 16.7% and resilient short-term momentum up 7.27% over two weeks.

This episode covers:
- **Current JNJ stock price** and trading volume analysis showing 6M shares traded
- **Price forecast** ranging from $242.99 to $257.53 for March 2026
- **Analyst ratings**: Consensus Moderate Buy with Morgan Stanley's $262 price target
- **Institutional trading activity** including recent moves...

# Johnson & Johnson Stock Analysis: JNJ Trading Update, FDA Approval & Analyst Price Targets | Healthcare Stock Podcast

**Episode Description:**

Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade at $242.79, down 0.38% from the previous close. This comprehensive episode covers JNJ's impressive performance with 18% year-to-date gains and 57% growth over the past year, reaching a massive $587 billion market cap.

Discover key catalysts driving the healthcare giant, including FDA approval of TECVAYLI plus DARZALEX FASPRO for multiple myeloma treatment, which strengthens Johnson & Johnson's oncology portfolio. Learn about the $65 million Tracleer antitrust settlement and what it means for...

# Johnson & Johnson Stock Analysis: JNJ Trading at $240.40 with Analyst Upgrades | March 2026 Market Update

Discover the latest **Johnson & Johnson (JNJ) stock analysis** as shares trade at $240.40 on March 10, 2026. This comprehensive podcast episode breaks down JNJ's current market position, featuring recent analyst upgrades from Wolfe Research and Daiwa Capital Markets.

In this episode, we examine:
- **JNJ stock price movement**: Up 0.32% with trading volume exceeding 7.1 million shares
- **Analyst consensus and price targets**: 26 analysts project targets averaging $199-$237, with recent upgrades to "outperform" and "strong buy" ratings
- **Dividend information**: $1.30 quarterly dividend with 0.636% yield
...

# Johnson & Johnson (JNJ) Stock Analysis: Strong Momentum at $240+ with Bullish Analyst Targets | Market Update 2024

Dive into the latest **Johnson & Johnson stock analysis** as JNJ shares trade above $240, showcasing impressive momentum in the pharmaceutical and healthcare sector. This comprehensive episode examines JNJ's recent performance, including its $579.75 billion market cap and solid Q1 earnings of $2.46 EPS on $24.28 billion revenue.

Discover why 27 Wall Street analysts maintain a **"moderate buy" consensus** with an average price target of $234.87. We break down recent upgrades from major firms including **Citigroup's $250 target**, **Morgan Stanley's $262 overweight rating**, and **Argus's boost to $240**.

Key highlights...

# Johnson & Johnson (JNJ) Stock Analysis: March 2025 Update | Price Targets, FDA Approvals & Investment Outlook

**Meta Description:** Johnson & Johnson stock (JNJ) analysis for March 2025. Discover latest price targets from JPMorgan, HSBC, and other analysts, FDA fast-track approvals, dividend yield, and whether the recent dip to $239 presents a buying opportunity.

---

**Episode Description:**

Dive into a comprehensive analysis of **Johnson & Johnson stock (JNJ)** following its recent market movements in early March 2025. This episode breaks down JNJ's performance as the stock dipped 2.3% to $239.65 despite trading above its closing price of $245.30.

**Key topics covered:**
<...

# SEO-Friendly Podcast Episode Description

## Johnson & Johnson Stock Analysis: March 5, 2026 Market Update | JNJ Trading at $154.22

Dive into today's comprehensive analysis of **Johnson & Johnson (JNJ) stock performance** on March 5, 2026. In this episode, we cover JNJ's current trading price of $154.22 per share, representing a 0.3% increase and demonstrating steady investor confidence in this healthcare industry leader.

**Key Topics Covered:**
- Real-time JNJ stock price and trading volume analysis
- Breaking news: Successful Phase 3 trial results for experimental rare lung disease treatment
- Q4 2025 earnings beat with $22.5 billion revenue (5% YoY growth)
- Latest analyst ratings...

# SEO-Friendly Podcast Episode Description

**Johnson & Johnson (JNJ) Stock Analysis: March 2026 Market Update & Positive Phase 3 Trial Results**

Discover the latest insights on Johnson & Johnson stock (NYSE: JNJ) trading at $154.22 per share as of March 4, 2026. In this comprehensive market analysis episode, we cover:

📈 **Key Highlights:**
- Current JNJ stock price showing 0.3% daily gain
- Breakthrough Phase 3 trial results for inflammatory bowel disease treatment
- Q4 2025 earnings beat with $22.47B revenue (up 6.5% YoY)
- Bullish analyst ratings from Barclays ($175 target) and Oppenheimer ($170 target)

💰 **Investment Fundamentals:**
- Attractive 3.1% dividend yield
- Unde...

# Johnson & Johnson Stock Surges: Q4 2025 Earnings Beat & Breakthrough Cardiac Study Drive Momentum | JNJ Stock Analysis

Johnson & Johnson (JNJ) stock continues its impressive rally, trading near $243 with strong momentum following exceptional Q4 2025 earnings and breakthrough cardiac clinical trial results. In this episode, we break down the healthcare giant's recent performance, including its $24.6 billion quarterly revenue (up 9.1% YoY), 2026 guidance projecting $100 billion in sales, and the game-changing OMNY AF pilot study showing 90% freedom from atrial fibrillation.

**Key Topics Covered:**
- JNJ stock analysis and current trading levels ($243, market cap $586.79B)
- Q4 2025 earnings breakdown and 2026 operational sales...

# Johnson & Johnson Stock Hits New 52-Week High: Strong Performance & Positive Outlook for JNJ in 2026

**Podcast Episode Description:**

Discover why Johnson & Johnson stock (JNJ) is making headlines in February 2026! In this episode, we break down JNJ's impressive climb to a new 52-week high of $247.25, driven by a market cap approaching $593 billion.

**What You'll Learn:**
- **Latest Stock Performance**: Real-time analysis of JNJ's February 25th, 2026 trading at $246, with 7.2M share volume
- **Key Growth Catalysts**: FDA submission for Imaavy (nipocalimab), Tremfya's 3-year UC results, and Darzalex oncology momentum
- **Financial Outlook**: Management guidance...

# Johnson & Johnson (JNJ) Stock Analysis: Trading at $246.99 with Strong 51.5% Annual Gains | Healthcare Stock Update 2025

**Podcast Episode Description:**

Dive into the latest Johnson & Johnson (JNJ) stock performance analysis as shares trade at $246.99, marking impressive 51.5% annual gains and approaching 52-week highs. This comprehensive episode covers JNJ's current market position, trading volume trends, and why this mega-cap healthcare giant with a $593.53 billion market cap continues to attract investor attention.

Discover key financial metrics including:
- Current trading range and volume analysis ($244.22-$247.25)
- Dividend yield of 2.09% and P/E ratio of 22.28
- Q4 earnings...

# Johnson & Johnson (JNJ) Stock Analysis: Trading Near 52-Week High with Strong Dividend Yield | Market Update 2024

**Podcast Episode Description:**

Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade at $245.78, up 1.3% and approaching the 52-week high of $246.96. This comprehensive market update covers JNJ's impressive performance with a $592 billion market cap, 2.12% dividend yield, and recent quarterly dividend of $1.30 per share.

**In This Episode:**
- Current JNJ stock price analysis and trading volume metrics
- 52-week performance review: from $141.50 low to near-record highs
- Dividend information and ex-dividend date details
...

# Johnson & Johnson (JNJ) Stock Analysis: Analyst Upgrades Push Price Target to $250+ | February 2026 Update

**Podcast Episode Description:**

Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade around $242-$247 with a massive $584 billion market cap. This episode breaks down recent bullish analyst moves, including TD Cowen's price target upgrade to $250, Wells Fargo's overweight rating at $240, and RBC Capital's ambitious $255 target.

**Key highlights covered:**
- **Stock Performance:** JNJ gained 0.83% on February 20, 2026, closing at $246.90
- **Analyst Consensus:** Multiple firms upgrade ratings with buy recommendations
- **Dividend News:** Quarterly dividend increased to $1.30 per...

# Johnson & Johnson Stock Analysis: Strong Momentum & Growth Potential | Investment Insights Podcast

Discover why Johnson & Johnson (JNJ) is capturing investor attention with its impressive 11.3% 30-day return and strategic billion-dollar expansion plans. In this episode, we analyze JNJ's current market position at $245.35, examine its solid fundamentals with a $590.26B market cap, and break down recent analyst upgrades from Morgan Stanley and RBC Capital. We explore how FDA approvals for simplified RYBREVANT dosing could boost competitiveness, evaluate the 2.1% dividend yield for income investors, and discuss growth projections through 2026. Perfect for healthcare sector investors seeking both dividend income and capital appreciation opportunities...

# JNJ Stock Analysis: Price Targets, Analyst Upgrades, and Market Trends

In this insightful episode, we examine Johnson & Johnson's (JNJ) recent market performance and future outlook. With JNJ closing at $243.45 yesterday, up $24.83 over the past month, we break down what investors need to know about this healthcare giant's trajectory.

## Episode Highlights:

- **Price Target Analysis**: Discover why RBC Capital raised its target to $255 while Goldman Sachs maintains a "Buy" rating with a $250 objective
- **Trading Volume Insights**: Learn what JNJ's reduced trading volume (3.26M shares vs. 9.24M average) signals about investor sentiment
...

# JNJ Stock Analysis: Johnson & Johnson Shows Strong Growth Amid MedTech Success

In this episode, we dive deep into Johnson & Johnson (JNJ) stock, currently trading at $243.45 with an impressive 17.5% year-to-date gain. Learn why this healthcare giant is approaching its 52-week high and what's driving its momentum. We explore JNJ's thriving MedTech segment with its $34 billion in sales and 15 new product launches, while examining potential challenges from Chinese procurement issues and tariff impacts.

Hear our breakdown of analyst ratings showing a "Moderate Buy" consensus from 26 experts, with price targets suggesting modest upside potential. We also analyze key technical...

# SEO-Friendly Podcast Description

## Johnson & Johnson Stock Analysis: Expert Forecasts, Valuations & Growth Potential | Quiet Please Podcast

In this insightful episode, we dive deep into Johnson & Johnson's current market position, with the stock trading around $243.43 per share. Discover what leading analysts are forecasting for JNJ stock, including predictions from thirty-rates.com, MarketBeat's analysis of increased trading volumes, and multiple analyst upgrades from major firms like Royal Bank of Canada and Citigroup.

We examine the contrasting valuation perspectives, from Simply Wall St's assessment of potential overvaluation amid talc litigation concerns to discounted cash flow models suggesting the...

# Johnson & Johnson (JNJ) Hits 52-Week High: Analyst Upgrades & Growth Potential

Discover why Johnson & Johnson stock (JNJ) reached a fresh 52-week high of $246.35, closing at $244.54 on Thursday with increased trading volume. This episode breaks down the recent analyst upgrades from Wells Fargo, Wolfe Research, TD Cowen, and Sanford C Bernstein, all pointing to strong growth potential for the healthcare giant. Learn about JNJ's current technical indicators showing bullish momentum, with the stock trading well above its 50-day moving average of $215.20. We analyze the company's latest quarterly performance ($24.28B revenue), market cap (~$589B), and attractive 2.1% dividend yield. Find out why...

# Johnson & Johnson (JNJ) Stock Analysis: Price Targets, Analyst Upgrades & Growth Potential

In this insightful episode, we examine Johnson & Johnson's impressive market performance as shares approach their 52-week high of $240.93. Discover why major investment firms including Morgan Stanley, Citigroup, and TD Cowen have recently upgraded their price targets and ratings to "Buy." We break down JNJ's latest quarterly earnings that beat revenue expectations with a 9.1% year-over-year increase, and analyze why Capital World Investors just opened a massive $2 billion position in the company. From institutional confidence to dividend yields and price projections for 2026, this comprehensive analysis provides everything investors need...

# Johnson & Johnson (JNJ) Stock Analysis: Tremfya Approval Boosts Outlook Amid Stability

Discover the latest Johnson & Johnson stock trends in this comprehensive analysis episode. We break down JNJ's recent market performance, including its February 10, 2026 close at $238.35, representing a marginal decline despite positive developments in its pharmaceutical portfolio. Learn how Tremfya's groundbreaking FDA approval as the first subcutaneous IL-23 treatment for ulcerative colitis is influencing investor sentiment.

Our episode examines key analyst ratings and price targets from major firms like Bernstein, revealing why 17 analysts maintain a "buy" consensus despite market fluctuations. We also explore significant technical indicators including...

# Johnson & Johnson (JNJ) Stock Analysis: Hitting 52-Week Highs with Mixed Analyst Outlooks

In this episode, we dive into Johnson & Johnson's impressive stock performance as JNJ reaches new 52-week highs around $240 per share. We explore the company's strong Q4 earnings report showing 9.1% revenue growth, analyze its attractive 2.2% dividend yield, and break down the varied analyst perspectives—from Morgan Stanley's bullish $262 target to long-term forecasts predicting potential growth to $288 by 2028. Discover why healthcare giant JNJ continues to demonstrate resilience despite ongoing litigation concerns, and what this means for investors considering this blue-chip stock in their portfolios.

Keywords: Johnson & Jo...

# "J&J's Financial Health: Analyzing Current Performance & Future Growth Potential"

In this insightful episode, we dive deep into Johnson & Johnson's current market position, where shares are trading near $240 with impressive 52-week gains. We unpack their recent Q4 results and ambitious 2026 revenue projections of approximately $100 billion, representing a 6.7% growth rate.

Our analysis covers the company's dividend strategy, delivering a 2.2% annual yield, and examines the mixed signals from Wall Street analysts. While firms like Wolfe Research, RBC Capital, and Goldman Sachs maintain bullish outlooks with price targets up to $255, we also address valuation concerns with the stock trading...

# Johnson & Johnson Stock Analysis: Undervalued Giant Shows Strong Market Momentum

In this insightful episode, we examine why Johnson & Johnson (JNJ) presents a compelling investment opportunity as shares trade around $238.16 despite showing nearly 5% growth in just one week. Our analysis reveals multiple valuation models suggesting significant undervaluation - with DCF analysis indicating a potential 37% discount to intrinsic value and another model projecting 19% upside.

We break down JNJ's impressive financial outlook, including management's projection of $21 billion in free cash flow by 2026, and examine recent strategic advances in their medtech and oncology divisions. While technical indicators show temporarily overbought...

# Johnson & Johnson Stock Analysis: Strong Growth & Analyst Optimism | Financial Markets Podcast

In this insightful episode, we dive deep into Johnson & Johnson's impressive market performance as shares trade near their 52-week high of $235.83. Discover how the pharmaceutical giant's $564 billion market cap and recent quarterly earnings beat of $24.56 billion are driving investor confidence. We analyze the company's projected 6.7% revenue growth for 2026, multiple analyst upgrades from firms including Citigroup and HSBC, and what the current P/E ratio of 21.13 means for investors. Whether you're considering adding JNJ to your portfolio or already holding shares, this comprehensive stock analysis provides valuable insights...

# Johnson & Johnson (JNJ) Stock Analysis: 52-Week High and Strong Earnings

In this episode, we dive into Johnson & Johnson's impressive market performance as JNJ shares trade near $233, approaching their 52-week high of $235.20. Discover how JNJ's strong quarterly earnings report propelled the stock upward, with revenue of $24.56 billion exceeding analyst expectations and representing a 9.1% year-over-year growth. We examine institutional sentiment as major firms like Wells Fargo, HSBC, and TD Cowen raise price targets, collectively maintaining a "moderate buy" consensus. Learn why JNJ's stability (beta of 0.35), consistent dividend yield of 2.2%, and healthcare sector positioning make this $562 billion market cap company worth...

# Johnson & Johnson Stock Update: Steady Gains Amid Lower Trading Volume | Market Analysis

Dive into our latest podcast episode where we analyze Johnson & Johnson's (JNJ) recent market performance. We break down JNJ's climb to $230.75 on February 2, 2026, representing a notable gain from its January 30th price of $227.25. Discover what decreasing trading volumes might signal for investor sentiment and how JNJ maintains its reputation as a stable dividend stock in today's healthcare market.

Our experts examine the pharmaceutical giant's resilience despite no major recent news or analyst updates, and why this matters for long-term investors seeking reliability in a...

# Exploring Johnson & Johnson's Stock Rally: Strong Earnings, Analyst Upgrades & Future Growth

Dive into our comprehensive analysis of Johnson & Johnson (JNJ) as the healthcare giant trades near its 52-week high. This episode unpacks JNJ's impressive Q4 2025 performance with 9.1% revenue growth, the recent dismissal of talc-related litigation, and multiple analyst upgrades pushing price targets above $260. We examine why trading volume has surpassed 11 million shares, exceeding daily averages and signaling heightened investor interest. Whether you're considering JNJ for its stable 2.3% dividend yield or evaluating its growth potential following European approval for AKEEGA and FDA clearance for DARZALEX FASPRO, this breakdown provides...

# Johnson & Johnson Stock Soars: Expert Analysis & Future Outlook | Investing Insights

Discover why Johnson & Johnson (JNJ) shares are trading at an impressive $227.32, reflecting a remarkable 55.27% surge over the past year. In this episode, we analyze the healthcare giant's recent fourth-quarter performance, where they exceeded revenue expectations with $24.56 billion and matched EPS projections at $2.46.

Listen as we break down Wall Street's bullish sentiment, including upgrades from Morgan Stanley and Goldman Sachs, with price targets suggesting significant upside potential. We explore JNJ's impressive financial outlook, with management projecting sales exceeding $100 billion and adjusted EPS of approximately $11.53 for 2026.

...

# Johnson & Johnson Stock Surges Following Stellar Q4 Results and Analyst Upgrades | Investment Analysis

Discover why Johnson & Johnson (JNJ) shares are gaining momentum as we analyze the stock's recent 1.5% climb to $227.70. This episode unpacks JNJ's impressive Q4 performance that exceeded Wall Street expectations, with quarterly revenue reaching $24.6 billion and EPS of $2.46. Learn about the company's ambitious FY2026 guidance projecting $100-101 billion in sales—surpassing consensus estimates by over $1.5 billion.

We examine the wave of analyst upgrades, including Morgan Stanley's notable shift from Equalweight to Overweight with a $262 price target suggesting nearly 17% upside potential. Find out why 14 of 26 an...

# Johnson & Johnson Stock Soars: Analyzing Q4 Results, 2026 Guidance & Analyst Optimism

In this episode, we break down Johnson & Johnson's impressive stock performance as shares surge to $224.50, up 1.4% in mid-day trading. Discover how J&J's solid Q4 results with $24.56B in revenue (up 9.1% YoY) and their bullish 2026 guidance of $99.5-100.5B in sales are driving investor confidence despite challenges like Stelara patent losses.

We analyze why top analysts are optimistic, with Guggenheim raising their price target to $240, Morgan Stanley upgrading to "Overweight" with a $262 target, and long-term forecasts predicting prices reaching $259 by April 2026. Learn how J&J's accelerated...

# Johnson & Johnson Stock Analysis: 50% Growth & 2026 Outlook - Quiet Please Podcast

In this insightful episode, we dive deep into Johnson & Johnson's impressive stock performance, which has surged 50% over the past year to reach approximately $220 by January 2026. We analyze the company's robust 31.64% year-to-date returns despite lighter-than-average trading volumes.

Our financial experts break down J&J's recent quarterly announcement, which revealed $25 billion in revenue and $6 billion in profit, along with their 2026 sales guidance that exceeded Wall Street expectations despite $500 million in tariff impacts and U.S. drug pricing pressures.

We explore current analyst sentiment, including the consensus "...

# Johnson & Johnson Stock Analysis: Strong Q4 Earnings, Bullish Outlook & Price Target Insights

In this episode, we dive into Johnson & Johnson's (JNJ) current market performance, trading at approximately $219.72 per share with technical indicators suggesting a bullish trend despite market fear. Discover how JNJ's impressive Q4 results—with revenue reaching $24.56 billion (up 9.1% year-over-year)—exceeded analyst expectations and what this means for investors. We explore the Trump administration deal reducing US drug prices while securing tariff exemptions and accelerating JNJ's $55 billion domestic manufacturing initiative. Plus, learn why analysts maintain a "moderate buy" consensus with price targets ranging from $212 to $250, supported by JNJ...

# Johnson & Johnson Stock Analysis: Growth Potential Despite Market Challenges

In this episode, we dive deep into Johnson & Johnson's latest stock performance and analyst projections. Discover why JNJ closed at $219.28 on January 22, 2026, with a 0.58% gain despite trading volume falling below recent averages. We explore multiple analyst upgrades, including Bank of America's new $221 target and Scotiabank's bullish $265 forecast, suggesting significant upside potential.

Learn about J&J's impressive Q4 earnings, where they reported $2.46 EPS and $24.56 billion in revenue—representing 9.1% year-over-year growth. We analyze their strong FY2026 guidance of $11.43-$11.63 EPS that exceeded market expectations and why analysts see double-digit re...

# Johnson & Johnson (JNJ) Beats Expectations: Strong Growth Despite Challenges | Investing Insights Podcast

Discover why Johnson & Johnson stock remains resilient despite recent profit-taking. In this episode, we analyze JNJ's impressive Q4 2025 performance, with revenue jumping 9.1% to $24.56 billion and management's optimistic 2026 guidance exceeding Wall Street projections. Learn how oncology powerhouses Darzalex and Tremfya are driving growth while the company navigates Stelara competition and litigation challenges. With analysts maintaining a "Moderate Buy" consensus and a reliable 2.4% dividend yield, find out why JNJ continues to attract long-term investors seeking stability in an uncertain market. Subscribe now for more expert analysis on blue-chip...

# "J&J Earnings Preview: Stock Near 52-Week High as Q4 Results Approach"

In this episode, we analyze Johnson & Johnson's stock performance as it trades near record levels ahead of crucial Q4 earnings. We explore how J&J shares closed at $218.22 on January 20, 2026, sitting just below the 52-week high of $220.09 and representing impressive year-to-date gains of approximately 48% from its 52-week low of $141.42.

Our analysis covers recent trading patterns, including volume trends and price movements, alongside Wall Street sentiment where analysts maintain predominantly bullish ratings. We break down notable price target upgrades from major firms like Goldman Sachs ($240...